Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

BACKGROUND: Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an immediate-release oral tablet for daily administration and as a long-acting injectable suspension (long-acting CAB [CAB LA]) for intramuscular...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:PLoS Med
Główni autorzy: Landovitz, Raphael J., Li, Sue, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y., Magnus, Manya, Hosseinipour, Mina C., Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A., Hendrix, Craig W., Eshleman, Susan H., Zhang, Yinfeng, Tolley, Elizabeth, Sugarman, Jeremy, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R., Margolis, David, Spreen, William R., Cohen, Myron S., McCauley, Marybeth, Eron, Joseph J.
Format: Artigo
Język:Inglês
Wydane: Public Library of Science 2018
Hasła przedmiotowe:
Research Article
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6224042/
https://ncbi.nlm.nih.gov/pubmed/30408115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002690
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy